. . . "synthesis" . "2011-08-08+02:00"^^ . . "28"^^ . " selectivity index" . "28"^^ . " molecular modelling" . "2013-10-31+01:00"^^ . "Several new series of in vitro antibacterial active compounds were obtained by molecule optimisation. The most effective are esters and carbamates of salicylanilides active against MDR and XDR strains of tuberculosis in MIC of 0.125 - 0.250 micromol/L."@en . "Hodnocen\u00ED a v\u00FDvoj nov\u00FDch perspektivn\u00EDch antituberkulotik a jejich prol\u00E9\u010Div aktivn\u00EDch v\u016F\u010Di multirezistentn\u00EDm kmen\u016Fm" . . . "2011-12-31+01:00"^^ . "N\u00E1r\u016Fst resistence u patogenn\u00EDch mikroorganism\u016F jako je Mycobacterium tuberculosis a zvy\u0161uj\u00EDc\u00ED se procento populace se sn\u00ED\u017Eenou imunitou je alarmuj\u00EDc\u00ED a pat\u0159\u00ED mezi prioritn\u00ED oblast \u0159e\u0161en\u00ED WHO. Aplikovan\u00FD mezioborov\u00FD v\u00FDzkum a v\u00FDvoj nov\u00FDch potenci\u00E1ln\u011B antimikrobi\u00E1ln\u011B aktivn\u00EDch l\u00E9\u010Div a prol\u00E9\u010Div p\u016Fsob\u00EDc\u00EDch p\u0159edev\u0161\u00EDm proti lidsk\u00FDm mykobakteri\u00E1ln\u00EDm patogen\u016Fm, v\u010Detn\u011B multirezistentn\u00EDch forem (MDR, XDR) Mycobacterium tuberculosis. \u0158e\u0161en\u00ED je zalo\u017Eeno na molekulov\u00E9m modelov\u00E1n\u00ED a synt\u00E9ze l\u00E1tek a hodnocen\u00ED jejich antimikrobi\u00E1ln\u00ED aktivity in vitro a hled\u00E1n\u00ED nov\u00FDch mechanism\u016F aktivity s ohledem na \u010Dast\u00FD v\u00FDskyt rezistence u sou\u010Dasn\u00FDch, konven\u010Dn\u00EDch prepar\u00E1t\u016F." . " prodrug" . "Evaluation and development of new perspective antimycobacterial drugs and prodrugs active against multidrug resistant strains"@en . . "NS10367" . . . . " clinical isolate" . "Optimalizac\u00ED molekul bylo z\u00EDsk\u00E1no n\u011Bkolik publikovan\u00FDch s\u00E9ri\u00ED in vitro antibakteri\u00E1ln\u011B \u00FA\u010Dinn\u00FDch slou\u010Denin, z nich\u017E nej\u00FA\u010Dinn\u011Bj\u0161\u00ED jsou estery a karbam\u00E1ty salicylanilid\u016F p\u016Fsob\u00EDc\u00ED v\u016F\u010Di MDR a XDR kmen\u016Fm tuberkul\u00F3zy v koncentrac\u00EDch MIC 0,125 - 0,25 mikromol/L."@cs . "synthesis; in vitro testing; prodrug; enzyme study; resistance; selectivity index; clinical isolate; molecular modelling; cytotoxicity"@en . "2009-01-01+01:00"^^ . . " in vitro testing" . "0"^^ . . " enzyme study" . "1"^^ . . "1"^^ . . . . . "The growth of resistance in etiologic microorganisms, including Mycobacterium tuberculosis, and the increasing number of people in the population with reduced immunity is quite significant, as noted by the World Health Organization (WHO). This is an applied research and development project, focused on the generation of new potential antimicrobial active drugs and prodrugs which act predominantly against isolated human pathogens and MDR strains of Mycobacterium tuberculosis. We aim to carry out the proposed investigation using molecular modeling, synthesis, biological evaluation in vitro and searching for new mechanisms of action."@en . " resistance" . "http://www.isvav.cz/projectDetail.do?rowId=NS10367"^^ . .